Martin joined Novo A/S in 2003 working out of their London office. He is chairman of the board of directors of Vantia Therapeutics Ltd, and a member of the board of directors of Epsilon-3 Bio Ltd, Funxional Therapeutics Ltd, KalVista Pharmaceuticals Ltd, Karus Therapeutics Ltd and Tarsa Therapeutics Inc. He is an adjunct professor at the Scandinavian International Management Institute. He was a board member at Serentis Ltd, Symphogen A/S and Thiakis Ltd. From 1998-2003, Martin was the CEO of ReNeuron Holdings, taking that company public in 2000 and raising a total of £25m in equity and debt financing. From 1994-1998, he was Corporate VP and Head of Drug Development for Novo Nordisk A/S where he was responsible for all aspects of pre-clinical and clinical drug development. Previously, Martin worked for six years in the USA first as VP Pharmacology and Medical Affairs of ZymoGenetics Inc in Seattle, and then as Senior VP for Medical Affairs at Novo Nordisk in Princeton N.J.